DreaMed Diabetes

DreaMed Diabetes is an Israeli healthtech company focused on software for diabetes treatment management, specifically the algorithmic optimization of insulin dosing for patients using continuous glucose monitors (CGM) and insulin pumps.

The company's primary product is Advisor Pro, a software platform aimed at endocrinologists and diabetes clinics. Advisor Pro ingests CGM and insulin pump data and generates algorithm-driven recommendations for adjusting a patient's insulin therapy. The product has received FDA clearance in the United States and CE marking in Europe, placing DreaMed among the few companies with dual regulatory approval for a clinical decision-support system in diabetes management.

Detailed public information on revenue, headcount, and funding structure is limited.